StemCell Therapy

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company’s research and development programs.

Here is the original post:
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline

View post:
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline

This marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products

See original here:
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore

LAUPHEIM, Germany and MILFORD, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that the company’s new state-of-the-art production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC), in Milford, MA in the U.S. is now fully operational. The company has a major project underway at the new line, with several additional projects in the pipeline, and continues to welcome new projects and clients.

Continued here:
Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational

CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced an agreement by which Beacon will evaluate Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications.

Go here to read the rest:
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204...

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance

More here:
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A?Os) for the treatment of Alzheimer’s disease (AD), today announced that the Company will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer’s Association International Conference (AAIC®) 2024 taking place in Philadelphia and online from July 28 – Aug. 1, 2024. The posters expand upon biomarker data associated with sabirnetug, methods for detecting levels of sabirnetug in cerebrospinal fluid (CSF), and provide insights on patients’ experiences in the INTERCEPT-AD study to inform future clinical trial considerations for sabirnetug.

Originally posted here:
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association...

BOCA RATON, Fla., July 11, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (“Entero” or the “Company”) (NASDAQ: ENTO), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,762,674 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.09 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $1,921,315, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.

More:
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Robert “Bobby” Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea’s accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations.

Original post:
Fortrea Appoints Robert Parks as Chief Accounting Officer

Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025 Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025

Continue reading here:
3Daughters Secures $4.7 Million in Oversubscribed Seed Round

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo’s ongoing SUNRISE-FA Phase 1/2 clinical trial (NCT05445323) and the ongoing Weill Cornell Medicine investigator-initiated trial (NCT05302271), as well as an overview of program next steps.

View post:
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia...

NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal

Original post:
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults

First Licensing Agreement for coactiv+™ Scalp Care Line First Licensing Agreement for coactiv+™ Scalp Care Line

Follow this link:
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.

SALT LAKE CITY, July 11, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced plans to submit a briefing book by July 13 to the U.S. Food and Drug Administration (FDA) in advance of a granted Type C interaction. The purpose of the interaction with the FDA, to occur in the third quarter of 2024, is to receive feedback on the potential path to submission of a new drug application (NDA) for CNM-Au8® as a potential treatment for ALS via the accelerated approval pathway.

Read the original:
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA...

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company’s freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing.

See the original post here:
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, July 23, 2024 at 10:00 AM ET.

Read the original here:
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Despite spending more than double on health care per citizen than most industrialized nations, the U.S. nears the bottom of the top 40 nations in health system rankings.Integrative & Lifestyle Medicine can change that.

Definition from the Academic Consortium of Integrative Medicine and Health: Integrative medicine and health reaffirms the importance of the relationship between practitioner and patient, focuses on the whole person, is informed by evidence, and makes use of all appropriate therapeutic and lifestyle approaches, healthcare professionals and disciplines to achieve optimal health and healing.

An Integrative Health practitioner uses all appropriate therapies, both conventional and complementary, to facilitate healing and promote optimal health. In the past several decades, the United States has seen a dramatic increase in morbidity from preventable illnesses such as obesity, heart disease, cancer and diabetes.

View Clinical Care at UC Health

People today want to take responsibility for their well-being by addressing the effects of lifestyle, emotions, and social interactions on health. People with certain health conditions can greatly benefit from an integrative approach to care. Some of these conditions include:

Expand all

Collapse all

Definition from the American College of Lifestyle Medicine: Lifestyle medicine is a medical specialty that uses therapeuticlifestyleinterventions as a primary modality to treat chronic conditionsincluding,but not limited to,cardiovascular diseases, type 2 diabetes, and obesity.Lifestyle medicine-certified clinicians are trained to applyevidence-based,whole-person, prescriptive lifestyle change to treat and, when used intensively, often reverse such conditions. Applying the six pillars of lifestyle medicinea whole-food, plant-predominant eating pattern, physical activity, restorative sleep, stress management, avoidance of risky substances and positive social connectionsalso provides effective prevention for these conditions.

The American College of Lifestyle Medicine (ACLM)is the medical professional society for physicians and other professionals dedicated to clinical and worksite practice of lifestyle medicine as the foundation of a transformed and sustainable health care system.

Lifestyle medicine can address up to 80% of chronic diseases. A lifestyle medicine approach to population care has the potential to arrest the decades-long rise in the prevalence of chronic conditions and their burdensome costs. Patient and provider satisfaction often results from a lifestyle medicine approach, which strongly aligns the field with the Quintuple Aim of better health outcomes, lower cost, improved patient satisfaction, improved provider well-being, and advancement of health equity, in addition to its alignment with planetary health. Lifestyle medicine is the foundation for a redesigned, value-based and equitable healthcare delivery system, leading to whole person health.

Medical Sciences Building Suite 4358231 Albert Sabin WayPO Box 670582Cincinnati, OH 45267-0582

Mail Location: 0582Phone: 513-558-2310Fax: 513-558-3266Email: osher.integrative@uc.edu

Read the rest here:
What is Integrative & Lifestyle Medicine - UC Cincinnati

What is Integrative Medicine?

Integrative medicine (IM) is an emerging field that emphasizes the evidence-basedcombination of both conventional and alternative approaches to address the biological, psychological, social and spiritual aspects of health and illness.

Integrative Medicine practitioners usually take a holistic/total person approach to their patients. They understand that overall health and well-being is a combination of multiple factors, including genetics, physiology, the environment, personal relationships, health beliefs, and the power of a positive medical interaction. In some situations, Integrative Medicine modalities may achieve similar results to conventional medicine with fewer side effects, and may create a greater sense of individual self-efficacy.

Stanford contains an Integrative Medicine Center; hospital-wide functions such as massage and pet therapy; various clinic-specific programs; educators and researchers exploring integrative medicine; and individual practitioners who may be either trained in, or knowledgeable about and open to, various modalities.

The purpose of this website is to gather together in one place an easily accessible snapshot of where to find Integrative Medicine modalities and practitioners/researchers/educators at Stanford Medical Center. It will be regularly updated. If you find something missing, please contact the webmaster.

Link:
Integrative Medicine | Stanford Medicine

The Integrative Medicine Service provides evidence-based complementary therapies to improve our patients experiences, physical outcomes, emotional wellness, and quality of life.

Our diverse multidisciplinary team includes medicine, acupuncture, massage therapy, creative arts therapies, mind-body therapies, and exercise. We offer a patient-centered approach that evaluates and helps people manage the emotional burden of their diagnosis and complications that arise from cancer treatment.

Our team of experts provides nurturing therapies that address chronic issues such as pain, neuropathy, fatigue and insomnia, stress, anxiety, mobility, and more.

Since 1999, our Integrative Medicine Service has been leading the field in innovative, patient-centered research. Our doctors and researchers studying how integrative therapies can be used to better control or reduce the side effects of cancer treatment.

Through activities like fellowships, onsite training programs, online courses, and our award-winning About Herbs library, we teach and train health care providers about best clinical practices, and the value of integrative medicine in cancer care.

About HerbsExplore MSKs award-winning About Herbs online library and mobile app for objective information on the potential benefits and risks of using dietary supplements and herbal products.

Continuing Education& TrainingOur online continuing education courses and onsite training opportunities prepare doctors, acupuncturists, nurses, and integrative health specialists to practice evidence-based integrative cancer care in their local community. MSK faculty members design every program with your needs and those of people with cancer everywhere in mind.

Refer a PatientFind out how to refer a patient to MSKs team of integrative medicine doctors and therapists, who provide a spectrum of care to people with cancer.

Research & Clinical TrialsDiscover how MSK helps move the field of integrative oncology forward through high-quality studies, many of which are open at any given time.

More here:
Integrative Medicine Service - Memorial Sloan Kettering Cancer Center

Integrative medicine includes the full spectrum of physical, emotional, mental, social, spiritual, and environmental factors that influence your health. This comprehensive, customized, whole-person approach to health care is beneficial, whether you want to maintain optimal health or you are coping with an ongoing condition. In both cases, our services improve how your physical body interacts with your psychological and emotional well-being.

A Place to RelaxDuke Integrative Medicine Centers healing environment features spa-like amenities including a whirlpool, sauna, steam room, meditation spaces, walking labyrinth, library, quiet room, contemplative gardens, and more. Our spacious, wood-paneled front hall sits at the edge of Duke Forest and is surrounded by floor-to-ceiling windows. Wait for your appointments in our comfortable waiting rooms.

Our circular library features relaxing, leather seating, and a soaring, cathedral ceiling. Our sun-drenched quiet room is filled with bamboo that stretches to reach the glass walls high above. Use our transition rooms to prepare for fitness activities, acupuncture, massage, and one-on-one yoga sessions.

Attend our many programs, workshops,and professional training in our spaces designed for large gatherings.

Our Environmentally-Conscious FacilityThe Duke Integrative Medicine Center is a 27,000-square-foot facility on the Duke Center for Living Campus, at the edge of Duke Forest and near Duke University Hospitaland Duke Clinic. Our spaces are available to Duke groups for rental.

Our building was designed in line with our commitment to conservation and sustainability. We were the first Leadership in Energy and Environmental Design (LEED) certified medical building in North Carolina.

We Are Committed to Education and TrainingPart of our mission is to educate a new generation of health professionals to provide integrative approaches that benefit their patients.

We Offer Clinical TrialsThrough our partnerships, you may have access to clinical trials that will help provide more information about elements of integrative medicine and their impacts over time.

Our Leaders Are Nationally RecognizedOur providers are also nationally recognized leaders who are using new models of medicine, education, and research to help shape the future of health care.

Follow this link:
Duke Integrative Medicine Center | Durham, NC | Duke Health